Anna Sureda, Paul A Carpenter, Andrea Bacigalupo, Vijaya Raj Bhatt, Josu de la Fuente, Aloysius Ho, Leslie Kean, Jong Wook Lee, Isabel Sánchez-Ortega, Bipin N Savani, Johannes Schetelig, Edward A Stadtmauer, Yoshiyuki Takahashi, Yoshiko Atsuta, John Koreth, Nicolaus Kröger, Per Ljungman, Shinichiro Okamoto, Uday Popat, Robert Soiffer, Heather E Stefanski, Mohamed A Kharfan-Dabaja
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism...
March 5, 2024: Bone Marrow Transplantation